Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
3 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Outlook Therapeutics, Inc.’s names, not what it holds today.
Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
10
since 2001, to Dec 31, 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Oncobiologics, Inc. a former name
named as the applicant on its applications, in US
7 publishedOutlook Therapeutics, Inc. its own name
US, as the owner printed on each patent
0 publishedOutlook Therapeutics, Inc. its own name
named as the applicant on its applications, in US
2 publishedOncobiologics, Inc. a former name
US, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 29, 2022 | 11,285,210 | Buffer formulations for enhanced antibody stability | Pharmaceuticals | Outlook Therapeutics, Inc. |
| Jun 30, 2020 | 10,696,735 | Modulation of charge variants in a monoclonal antibody composition | Biotechnology | Outlook Therapeutics, Inc. |
| Aug 13, 2019 | 10,376,582 | Buffer formulations for enhanced antibody stability | Pharmaceuticals | Outlook Therapeutics, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 19, 2021 | 2021/0255194 | METHODS FOR IDENTIFYING AND ANALYZING AMINO ACID SEQUENCES OF PROTEINS | Analysis of biological materials | Oncobiologics, Inc. |
| Jul 29, 2021 | 2021/0230261 | BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES | Pharmaceuticals | Outlook Therapeutics, Inc. |
| May 30, 2019 | 2019/0161543 | MODULATION OF AFUCOSYLATED SPECIES IN A MONOCLONAL ANTIBODY COMPOSITION | Biotechnology | Outlook Therapeutics, Inc. |
| Feb 14, 2019 | 2019/0048070 | REDUCTION OF HIGH MOLECULAR WEIGHT SPECIES, ACIDIC CHARGE SPECIES AND FRAGMENTS IN A MONOCLONAL ANTIBODY COMPOSITION | Biotechnology | Oncobiologics, Inc. |
| Jan 31, 2019 | 2019/0030163 | BUFFER FORMULATIONS FOR ENHANCED ANTIBODY STABILITY | Pharmaceuticals | Oncobiologics, Inc. · patent 11,285,210 granted from it |
| Jan 17, 2019 | 2019/0016817 | BUFFERED FORMULATIONS OF BEVACIZUMAB | Pharmaceuticals | Oncobiologics, Inc. |
| Jan 17, 2019 | 2019/0016753 | METHODS FOR SEPARATING ISOFORMS OF MONOCLONAL ANTIBODIES | Biotechnology | Oncobiologics, Inc. |
| Jan 11, 2018 | 2018/0009876 | MODULATION OF CHARGE VARIANTS IN A MONOCLONAL ANTIBODY COMPOSITION | Chemical engineering | Oncobiologics, Inc. · patent 10,696,735 granted from it |
| Aug 18, 2016 | 2016/0235845 | Buffer Formulations for Enhanced Antibody Stability | Pharmaceuticals | Oncobiologics, Inc. · patent 10,376,582 granted from it |
| Jul 3, 2014 | 2014/0186365 | ANTIBODIES THAT SPECIFICALLY BIND TO SERUM ALBUMIN WITHOUT INTERFERING WITH ALBUMIN'S CAPABILITY TO INTERACT WITH THE FCRN | Biotechnology | Oncobiologics, Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.